This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
The guidance comes after two years of consulting with hundreds of stakeholders, including indigenous peoples, religious leaders, patient groups, and scientists.
The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.